← Back to screener

Kyverna Therapeutics, Inc. KYTX

Rank #1670 · Nasdaq · $0.3B market cap
Audited by BDO USA, P.C., no going-concern flag in the latest filing.
Score
44.6
P/E
-2.7
P/B
-26.24
ROE
970.2%
Op. Margin
–%
Debt Ratio
-290%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -2.7x, P/B -26.24x. Ranks in the top 96% of the universe.

Profitability ★★★★★
Excellent

ROE 970.2%. Ranks in the top 0% of the universe.

Safety ★★★★★
Excellent

Debt ratio -290%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024–$-0.1B$-0.1B$-0.1B–-35
2025–$-0.1B$-0.1B$-0.0B–-290

← See the full screener